Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17949133 | 1.00 | GPR119 (0.48) | GPR119STSTGFBR1MMP13TP53 | |
| SCHEMBL17942344 | 0.88 | GPR119 (0.48) | GPR119STSTGFBR1MMP13TP53 | |
| SCHEMBL17942516 | 0.88 | GPR119 (0.48) | GPR119STSTGFBR1MMP13TP53 | |
| SCHEMBL17942564 | 0.84 | TSHR (0.40) | — | |
| SCHEMBL30833483 | 0.83 | RIPK1 (0.42) | GPR119 | |
| SCHEMBL16818231 | 0.79 | GPR119 (0.54) | GPR119STSTGFBR1MMP13TP53 | |
| SCHEMBL17942390 | 0.78 | CYP3A4 (0.54) | GPR119STSTGFBR1MMP13 | |
| SCHEMBL17942540 | 0.78 | GPR119 (0.56) | GPR119STSTGFBR1MMP13 | |
| SCHEMBL25573766 | 0.77 | GPR119 (0.47) | GPR119TP53 | |
| SCHEMBL17942389 | 0.76 | TGFBR1 (0.53) | GPR119STSTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | GPR119 3908/4885STS 2847/4885TGFBR1 2904/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | GPR119 3908/4885STS 2847/4885TGFBR1 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.